SCHEMBL14033447

SCHEMBL14033447

NC(=O)CNC(=O)c1cnn2cc(Cc3cccc(Cl)c3Cl)cnc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
PDE2A O00408 4/20 0.39
EPHB3 P54753 3/20 0.38
LMNA P02545 2/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
JAK2 O60674 1/20 0.36
NR3C1 P04150 2/20 0.36
STING1 Q86WV6 1/20 0.36
IRAK4 Q9NWZ3 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CMA1 P23946 1/20 0.35
JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14870460 0.90 HSD17B10 (0.49) HSD17B10KDM4EPKMPDE2AEPHB3
SCHEMBL14033701 0.84 IRAK4 (0.43) HSD17B10KDM4EPKMPDE2AJAK2
SCHEMBL14033455 0.84 IRAK4 (0.43) HSD17B10KDM4EPKMPDE2AJAK2
SCHEMBL14033169 0.82 PDE2A (0.42) HSD17B10KDM4EPKMPDE2ALMNA
SCHEMBL14033696 0.82 IRAK4 (0.42) HSD17B10KDM4EPKMPDE2AJAK2
SCHEMBL14033296 0.81 PDE2A (0.43) PDE2AJAK2IRAK4
SCHEMBL4437368 0.81 MRGPRX4 (0.42) HSD17B10KDM4EPKMPDE2A
SCHEMBL4439750 0.80 PDE2A (0.41) HSD17B10KDM4EPKMPDE2ALMNA
SCHEMBL4437012 0.79 KLKB1 (0.42) KDM4EPDE2AALDH1A1HPGDJAK2
SCHEMBL4434781 0.77 NR3C1 (0.47) HSD17B10KDM4EPKMPDE2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9358250-B2 Methods of using SCD1 antagonists GENENTECH, INC. (US) 2016-06-07 US disclosed
US-9358250-B2 Methods of using SCD1 antagonists GENENTECH, INC. (US) 2016-06-07 US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
WO-2008116898-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE BIOVITRUM AB (PUBL) (SE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255153-A1 New compounds SCD, SCD5, FADS2 HSD17B10 67/4885KDM4E 1192/4885PKM 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.